Results 231 to 240 of about 15,546 (262)
Some of the next articles are maybe not open access.
Mycoses, 2012
SummaryInvasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21st century as it is active against Candida species, Aspergillus ...
Dimitrios P. Kontoyiannis +2 more
openaire +2 more sources
SummaryInvasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21st century as it is active against Candida species, Aspergillus ...
Dimitrios P. Kontoyiannis +2 more
openaire +2 more sources
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem Temesgen +2 more
openaire +3 more sources
Micafungin for the treatment of invasive aspergillosis
Journal of Infection, 2014Invasive aspergillosis is a major cause of morbidity and mortality in immunocompromised patients, particularly those with neutropenia and those undergoing bone marrow or stem cell transplants. Micafungin is an echinocandin antifungal drug with activity against all major Candida spp.
Enoch, D. A. +5 more
openaire +3 more sources
Role of Micafungin in the Antifungal Armamentarium
Current Medicinal Chemistry, 2007Serious infections caused by opportunistic molds remain a major problem for public health. Immune deficiency following organ transplantation and aggressive cancer treatment has greatly increased the incidence of systemic mycoses, and invasive aspergillosis in patients with AIDS is associated with significant morbidity and mortality.
Hidenori Ohki +7 more
openaire +3 more sources
2009
Fungal infections are known to cause not only superficial diseases, such as athlete's foot and onychomycoses, but also those that become disseminated and life-threatening; serious invasive fungal infections caused by Candida spp., Cryptococcus neoformans, Aspergillus spp., Pneumocystis carinii and H...
Akihiko Fujie +2 more
openaire +2 more sources
Fungal infections are known to cause not only superficial diseases, such as athlete's foot and onychomycoses, but also those that become disseminated and life-threatening; serious invasive fungal infections caused by Candida spp., Cryptococcus neoformans, Aspergillus spp., Pneumocystis carinii and H...
Akihiko Fujie +2 more
openaire +2 more sources
Nebulizer Delivery of Micafungin Aerosols
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011Study Objectives. To determine the optimal nebulization system for aerosolizing micafungin and to further assess the physiochemical properties of aerosolized micafungin.Design. In vitro experiment.Setting. University research center.Nebulizers. Pari LC Star, Hudson Updraft, Small Volume Nebulizer, and Aeroclipse II.Measurements and Main Results.
Thomas P. Winkler +4 more
openaire +3 more sources
Mycoses, 2012
SummaryInvasive candidiasis and mucosal candidiasis are among the most important health care associated infections; in its invasive form, candidiasis is associated with substantial morbidity and mortality. Among the currently available antifungal agents, the echinocandins are the among the most potent agents against Candida species.
openaire +2 more sources
SummaryInvasive candidiasis and mucosal candidiasis are among the most important health care associated infections; in its invasive form, candidiasis is associated with substantial morbidity and mortality. Among the currently available antifungal agents, the echinocandins are the among the most potent agents against Candida species.
openaire +2 more sources
Breakthrough Candidemia In Children On Micafungin
Pediatric Infectious Disease Journal, 2018We identified 8 pediatric patients on micafungin (MCFG; ≥3 doses) at our institution who had breakthrough candidemia (BC). The causative strains of the BC were Candida parapsilosis in 7 patients. The minimum inhibitory concentration of MCFG was ≤1 µg/mL (susceptible) in all 8 isolates.
Takanori Funaki, Isao Miyairi
openaire +2 more sources
Expert Review of Anti-infective Therapy, 2011
Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children. The majority of IFIs are caused by Candida and Aspergillus species. Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome.
openaire +2 more sources
Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children. The majority of IFIs are caused by Candida and Aspergillus species. Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome.
openaire +2 more sources
Drugs of Today, 2002
FK-463 (micafungin) represents the latest development candidate in a novel chemical class of echinocandin lipopeptide antifungal compounds. This agent has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species (yeasts) and Aspergillus fumigatus (filamentous fungus). This compound has favorable pharmacokinetics
openaire +3 more sources
FK-463 (micafungin) represents the latest development candidate in a novel chemical class of echinocandin lipopeptide antifungal compounds. This agent has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species (yeasts) and Aspergillus fumigatus (filamentous fungus). This compound has favorable pharmacokinetics
openaire +3 more sources